spacer
home > pmps > autumn 2019 > reliable temperature control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Reliable Temperature Control





Most biologics require controlled temperature conditions throughout their lifecycle to maintain their efficacy and integrity. By some industry estimates, 25% of such drugs degrade or go to waste due to temperature excursions that result in $16 billion in economic losses and patient safety issues. The industry should aggressively adopt advances in packaging and information technologies such as Internet of Things (IoT) and blockchain to prevent temperature excursions in cold chains.

The Next Big Growth Markets

According to research, the biologics and biosimilar market is expected to reach $399.5 billion by 2025. More than 50% of new drug approvals in 2017 are biologics that require temperaturecontrolled environments, a trend that is anticipated to continue.

Biologics are large molecule drugs that contain a living organism or a component thereof, such as recombinant DNA and deactivated viruses. Biologic drugs are sensitive to their environmental conditions such as temperature, light exposure, humidity, shock, and vibrations and can degrade or spoil when exposed to conditions outside their stability range for a long period of time. Of all the environmental conditions, temperature stands out as the single biggest cause of drug degradation and spoilage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author


Sujan Thanjavuru is a digital transformation thought leader in the life sciences industry. For over 20 years, Sujan has been partnering with life sciences companies to help reduce time to market of new products and drive enterprise transformation across their value chain. He is also the founder of two health IT start ups, Clinical Data and SafeRxp. Both startups have developed innovative cloudbased cognitive platforms in partnership with Carnegie Mellon University, US. Sujan continues to build innovative new IT platforms that attempt to solve structural industry problems such as counterfeit drugs, broken cold chains, high cost of drug development, and serious adverse drug reactions.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Partners with Propeller Health to Gather Accurate Data on Asthma and COPD Medication Use

Philadelphia, PA – January 07, 2020: Signant Health announced today a partnership to connect TrialMax®, the industry-leading electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)

11-13 May 2020, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th 12th May 2020. HPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement